HQSI (Healthcare Quality Strategies, Inc)

hqsi.org

HQSI (Healthcare Quality Strategies, Inc.) provides independent medical review for private and government insurers, hospitals, third-party administrators and employers. As a URAC-certified review organization, and NAIRO member, HQSI conducts reviews in all key medical specialties always adhering to the highest ethical and professional standards.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

HERON THERAPEUTICS TO INITIATE PHASE 2 CLINICAL STUDY OF CINVANTI® FOR COVID-19 TREATMENT

PR Newswire | July 17, 2020

news image

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the initiation of the GUARDS-1 Study, a Phase 2 clinical study evaluating CINVANTI (aprepitant) injectable emulsion in early hospitalized patients with Coronavirus Disease 2019 (COVID-19). The study initiation follows clearance from the U.S. Food and Drug Admin...

Read More

Medical

MODERNA ANNOUNCES SUPPLY AGREEMENT WITH UK GOVERNMENT FOR ADDITIONAL 2 MILLION DOSES OF MRNA-1273, MODERNA’S VACCINE CANDIDATE AGAINST COVID-19

Moderna | November 30, 2020

news image

Moderna, Inc., a biotechnology organization pioneering messenger RNA (mRNA) therapeutics and vaccines to make new generation of transformative medicines for patients, today reported a supply agreement with the UK government for an extra 2 million doses of mRNA-1273, Moderna's vaccine candidate against COVID-19, to the United Kingdom starting in March 2021. The UK government has now made sure about 7 million dosages of mRNA-1273. This confirmation comes as the UK proceeds with its efforts to ...

Read More

Medical

HERON THERAPEUTICS ANNOUNCES FDA APPROVAL OF ZYNRELEF® INDICATION EXPANSION TO INCLUDE ADDITIONAL ORTHOPEDIC AND SOFT TISSUE PROCEDURES

Heron Therapeutics, Inc. | January 29, 2024

news image

Heron Therapeutics, Inc. a commercial-stage biotechnology company announced that the U.S. Food and Drug Administration (the "FDA") has approved its supplemental New Drug Application ("NDA") for ZYNRELEF® extended-release solution to expand the indication for soft tissue and orthopedic surgical procedures including foot and ankle, and other procedures in which direct exposure to articular cartilage is avoided. ZYNRELEF was previously approved for foot and ankle, smal...

Read More

Cell and Gene Therapy

INDYGENEUS AI SECURES PATHOGEN SEQUENCING FOR COVID-19 GENOMIC SURVEILLANCE INITIATIVES

IndyGeneUS AI | May 20, 2021

news image

Through collaborations, IndyGeneUS AI has acquired genomic analysis and testing capabilities. This pathogen sequencing capacity has emerged at a critical moment in efforts to improve genomic surveillance and monitor COVID-19 variant strains across the continent. IndyGeneUS founder and CEO Yusuf Henriques emphasized the importance of this work. "COVID-19 and its variants pose a danger to the entire African continent, so we must act quickly. Our partners understand the urgency ...

Read More
news image

HERON THERAPEUTICS TO INITIATE PHASE 2 CLINICAL STUDY OF CINVANTI® FOR COVID-19 TREATMENT

PR Newswire | July 17, 2020

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the initiation of the GUARDS-1 Study, a Phase 2 clinical study evaluating CINVANTI (aprepitant) injectable emulsion in early hospitalized patients with Coronavirus Disease 2019 (COVID-19). The study initiation follows clearance from the U.S. Food and Drug Admin...

Read More
news image

Medical

MODERNA ANNOUNCES SUPPLY AGREEMENT WITH UK GOVERNMENT FOR ADDITIONAL 2 MILLION DOSES OF MRNA-1273, MODERNA’S VACCINE CANDIDATE AGAINST COVID-19

Moderna | November 30, 2020

Moderna, Inc., a biotechnology organization pioneering messenger RNA (mRNA) therapeutics and vaccines to make new generation of transformative medicines for patients, today reported a supply agreement with the UK government for an extra 2 million doses of mRNA-1273, Moderna's vaccine candidate against COVID-19, to the United Kingdom starting in March 2021. The UK government has now made sure about 7 million dosages of mRNA-1273. This confirmation comes as the UK proceeds with its efforts to ...

Read More
news image

Medical

HERON THERAPEUTICS ANNOUNCES FDA APPROVAL OF ZYNRELEF® INDICATION EXPANSION TO INCLUDE ADDITIONAL ORTHOPEDIC AND SOFT TISSUE PROCEDURES

Heron Therapeutics, Inc. | January 29, 2024

Heron Therapeutics, Inc. a commercial-stage biotechnology company announced that the U.S. Food and Drug Administration (the "FDA") has approved its supplemental New Drug Application ("NDA") for ZYNRELEF® extended-release solution to expand the indication for soft tissue and orthopedic surgical procedures including foot and ankle, and other procedures in which direct exposure to articular cartilage is avoided. ZYNRELEF was previously approved for foot and ankle, smal...

Read More
news image

Cell and Gene Therapy

INDYGENEUS AI SECURES PATHOGEN SEQUENCING FOR COVID-19 GENOMIC SURVEILLANCE INITIATIVES

IndyGeneUS AI | May 20, 2021

Through collaborations, IndyGeneUS AI has acquired genomic analysis and testing capabilities. This pathogen sequencing capacity has emerged at a critical moment in efforts to improve genomic surveillance and monitor COVID-19 variant strains across the continent. IndyGeneUS founder and CEO Yusuf Henriques emphasized the importance of this work. "COVID-19 and its variants pose a danger to the entire African continent, so we must act quickly. Our partners understand the urgency ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us